Patients with the following conditions should not take semaglutide:
- diabetic retinopathy, a type of damage to the eye from diabetes
- low blood sugar
- disease of the gallbladder
- decreased kidney function
- medullary thyroid cancer
- multiple endocrine neoplasia type 2
- family history of medullary thyroid carcinoma
- kidney disease with likely reduction in kidney function
- pregnant or plan to become pregnant, breastfeeding or plan to breastfeed
U.S. Food and Drug Administration (FDA) has approved drugs that have semaglutide as an active ingredient – Wegovy, Ozempic, and Rybelsus. Like most medications, semaglutide has side effects. The most common mild side effects are nausea, diarrhea, vomiting, indigestion, and constipation. Semaglutide also may cause serious side effects, including inflammation of the pancreas (pancreatitis), changes in vision, low blood sugar (hypoglycemia), kidney problems (kidney failure), and serious allergic reactions.
Medical professionals say that semaglutide – Ozempic, Rybelsus and Wegovy’s active ingredient, is the furthest advanced and most promising weight-loss drug. In a 68-week trial, patients lost an average of 15% of their body weight taking semaglutide. However, participants, who introduced “healthy” changes to their lifestyle, lost 20% and more of their weight. And here’s how you can as well.
Semaglutide is injectable and has to be injected once weekly